

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application No.: 10/647,353
Attorney Docket No.: Q77194

REMARKS

The Office Action of November 2, 2005 has been received and its contents carefully considered.

Claims 1, 12, 13 15 to 19 and 23 to 29 are all the claims pending in the application.

Claim 28 has been rejected under the second paragraph of 35 U.S.C. § 112 as indefinite.

The Examiner states that it is not clear if the fused arylene group that is referred to in claim 28 relates only to the Ar¹², Ar²² and Ar³² groups of claim 27, or whether it also relates to the Ar¹¹, Ar²¹ and Ar³¹ groups of claim 1.

In response, the recitations in claim 28 refer only to the fused aryl group having at least four rings of claim 27, and do not refer to the Ar¹¹, Ar²¹ and Ar³¹ groups of claim 1. Applicant has amended claim 28 to make this clearer by stating in claim 28 that the fused group having at least four rings is the group represented by Ar¹², Ar²² and Ar³².

In view of the above, applicant requests withdrawal of this rejection.

Claims 1, 12, 13, 15, 16 and 25 have been rejected under 35 U.S.C. § 103(a) as obvious over the newly cited US Patent 6,352,791 to Fink et al.

Of the above claims, claims 1, 15 and 25 are independent.

With respect to claims 1 and 25, Fink et al perhaps suggest the perylenylene group in claim 1 and the anthrylene group and perylenylene groups that are recited in claim 25 for Ar¹¹, Ar²¹ and Ar³¹, but do not disclose or suggest the phenanthrenylene group, the pyrenylene group, the fluorenylene group, the chrysenylene group, or the triphenylene group of claim 25.

Accordingly, applicant has amended claim 1 to recite these groups. In addition, applicant has

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application No.: 10/647,353
Attorney Docket No.: Q77194

amended independent claim 15 to define Ar¹¹, Ar¹² and Ar³¹ in the same manner as in claim 1, and has canceled claim 25.

In view of the above, applicant requests withdrawal of this rejection.

Claims 17-19, 26 and 27 have been objected to.

In particular, the Examiner states that the “ene” suffix should not be used in the names for the groups represented by Ar¹², Ar²² and Ar³².

The Examiner states that upon correction of this point and rewriting of these claims in independent form, they would be allowable.

In response, applicant has amended these claims in the manner proposed by the Examiner, with claims 17, 26 and 27 being written in independent form.

In addition to the claims identified by the Examiner, claim 15 also contains the problem identified by the Examiner. In the above amendment to claim 15, applicant has amended claim 15 to respond to this point.

The Examiner indicates that claims 23, 24 and 29 contain allowable subject matter. Applicant has amended claims 23 and 29 to place them in independent form. Claim 24 already appears in independent form.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application No.: 10/647,353
Attorney Docket No.: Q77194

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Sheldon I. Landsman
Registration No. 25,430

Date: February 2, 2006